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Over the last years, the discovery ofmicroRNAs (miRNAs) has revolu-
tionized the classic concepts of gene
expression regulation and has introduced
a new group of molecules that may con-
tribute to the complex changes observed
during aging. Although several Caenorha-
bditis elegans miRNAs have been proved
to influence the nematode life span,
the current knowledge about miRNA-
mediated regulation of mammalian aging
is still limited. Recently, we have analyzed
the functional relevance of miRNAs in
accelerate aging by using Zmpste24-/-
mice, a murine model that phenocopies
Hutchinson-Gilford progeria syndrome.
These studies have revealed that the
nuclear abnormalities present in these
mice affect the expression levels of several
miRNAs, including a marked upregula-
tion of miR-1 and miR-29. Furthermore,
we have found that the altered expression
of these miRNAs may contribute to the
progeroid phenotype of mutant mice by
modulating the levels of key components
of the somatroph axis and DNA damage
response pathways. Here, we discuss
these recent discoveries and summarize
the present evidences regarding the
involvement of aging-associated miRNAs
or geromiRs in senescence and longevity
regulation.
Aging has been the objective of multiple
works for many years. This complex and
irremediable process associated with life
has a special interest for human popula-
tions due to the growing incidence of age-
associated chronic pathologies such as
diabetes, arthritis, neurological disorders,
cardiovascular diseases and cancer.1,2 The
proper understanding of the molecular
basis of aging may contribute to prevent or
attenuate these age-related alterations.
Despite the strong research effort aimed
to uncover the mechanisms that orches-
trate aging, its multifactorial nature has
hampered the acceptance of a consensus
theory for organismal aging. Nevertheless,
there is some agreement that a common
feature of aging is the progressive accu-
mulation of damaged cells, which com-
promises tissue homeostasis and function.
Over the last years, several stressors con-
tributing to aging have been identified,
including oxidative reactions, telomere
attrition and the decline of DNA repair
and protein turnover systems.1-3 At the
molecular level, the identification of gene-
tic mutations that cause accelerated aging
syndromes in humans has allowed the
characterization of several pathways that
influence organism longevity.4 These dis-
coveries have reinforced the role of DNA
damage in the process of aging, since the
vast majority of progeroid phenotypes are
due to mutations in genes involved in
genome maintenance or nuclear and
chromatin organization. Thus, mutations
in the nucleotide excision repair, homo-
logous recombination or double strand
break repair systems as well as in genes
involved in DNA damage signaling, cause
accelerate aging in humans.5 Similarly,
alterations in genes that encode nuclear
lamina proteins such as lamin A or BAF,
are responsible for the development of
different human progeroid laminopa-
thies.6-10 Analogously, several evolutionary
conserved stress-sensing circuits have
been recognized as important modulators
of aging, including the insulin/IGF-1
signaling, target of rapamycin (TOR),
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sirtuins and AMP-activated protein kinase
(AMPK) pathways.3,11 These stress res-
ponse pathways measure changes in para-
meters such as energy status, nutrient
availability, protein and DNA damage,
and oxidative potential, orchestrating
adaptive cellular responses aimed to pre-
serve protein and DNA functionality
during aging.
The Growing Relevance
of miRNAs in Aging
The recent discovery and functional char-
acterization of miRNAs has substantially
changed the classic view of gene expres-
sion regulation and has unveiled a new
group of molecules that contribute to the
complex process of aging.12-14 miRNAs are
small RNA molecules that directly bind to
the 3' untranslated regions (3'UTRs) of
their target transcripts and inhibit protein
production by mRNA degradation or
translational blockage (Fig. 1).15 miRNA-
mediated regulation is an extended pheno-
menon across animals and plants, which
has the ability to control a considerable
proportion of cellular transcripts. In
humans, around 500 miRNAs have been
validated and it has been estimated that
more than 60% of transcripts are suscept-
ible to miRNA regulation.16 Individually,
each miRNA has the potential to repress
tens to hundreds of transcripts, a feature
that allows them to modulate the levels of
several components of a single pathway or
to affect the activity of related pathways
through the regulation of different key
elements. In addition, their frequent
organization in genomic clusters that
coexpress different miRNAs further
increases the range of potentially targeted
pathways and functions. Thus, these
molecules play important roles in almost
every process of the cell, such as prolifera-
tion, differentiation, migration, apoptosis,
senescence and autophagy. Likewise,
miRNA activity is essential during embry-
onic development and in numerous
physiological and pathological processes,
including cancer.17,18
On this basis, it was also tempting to
speculate that miRNAs could be suitable
candidates for aging modulation. The first
studies aimed to address this question
were performed in C. elegans and led to
the finding that miRNAs may influence
Figure 1. miRNA biogenesis and mechanism of action. miRNAs are transcribed in the nucleus as long primary transcripts (pri-miRNAs) that acquire a
characteristic stem loop secondary structure. This structure is recognized by Drosha RNase III, which releases the ~70-nt precursor miRNAs (pre-miRNAs)
that are then transported to the cytoplasm by exportin-5/Ran-GTP complexes. Once in the cytoplasm, they are processed by Dicer RNase III into 22-nt
double stranded miRNAs (miRNA duplexes). Finally, one strand, which represents the mature miRNA, is incorporated into the RNA-induced silencing
complex (RISC), which will mediate the repression of the target genes by direct cleavage of the mRNAs, by deadenylation and subsequent mRNA decay,
or by translational blockage.
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the longevity of this organism. Thus,
Boehm et al.19 demonstrated that lin-4
miRNA loss-of-function mutants have
shortened lifespan when compared with
wild-type animals. They also reported that
lin-4 overexpressing nematodes or the
knockdown mutants of its target gene,
lin-14, display the opposite effect. Like-
wise, de Lencastre et al.20 found four
miRNAs (miR-71, miR-238, miR-239
and miR-246) whose loss-of-function sig-
nificantly extends or shortens C. elegans
longevity. Further genetic analysis has
revealed that some of these miRNAs act
through the modulation of known aging
circuits like the DNA damage response
and the insulin-signaling pathways.20 In
mammals, however, the current know-
ledge about the implication of miRNAs
in aging regulation is still very limited.
Profiling studies in liver and brain from
aged mice have revealed changes in
miRNA expression during aging, whereas
paradoxical results have been obtained in
lung.21-24 Similarly, differential miRNA
expression levels have been found in
human skeletal muscle and peripheral
blood mononuclear aging cells.25,26 Hackl
et al.27 have also reported the down-
regulation of several miRNAs in human
foreskin, mesenchymal stem cells and
CD8+ T cell populations from old and
young donors. Likewise, Somel et al.28
have recently analyzed the changes in
miRNA, mRNA and protein levels in
human and macaque brain and have
found solid evidences of miRNA-mediated
regulation of gene expression during
aging. Additionally, several miRNAs are
deregulated in the Ames dwarf mice,
and miR-27 has been proposed to play
a role in the delayed aging observed in
these animals.29
miRNAs, Nuclear Envelope
and Premature Aging
Although the above evidences strongly
suggest the implication of miRNAs in
aging modulation, no studies in this
regard had been performed in premature
aging mice until our recent work dem-
onstrating that mir-29 is overexpressed in
Zmpste24-null mice.30 These mutant ani-
mals exhibit profound nuclear envelope
abnormalities and are an excellent model
of Hutchinson-Gilford progeria syndrome
(Fig. 2).31,32 Previous work from our labo-
ratory had already suggested that miRNAs
could contribute to the progeroid pheno-
type characteristic of Zmpste24-deficient
mice.33 In fact, we had observed that the
significant upregulation of miR-1 in the
liver from these mutant mice could target
the mRNA for insulin-like growth factor-1
(Igf-1) and be partially responsible for the
marked deregulation of the somatotroph
axis signaling found in these animals.34
Based on these results, and considering
that different murine models with accel-
erate aging have yielded important clues
about molecular mechanisms of aging,4,5
we profiled the miRNA expression levels
in Zmpste24-deficient mice.30 This analysis
revealed that the three members of the
miR-29 family of miRNAs displayed a
significant upregulated expression in liver
and muscle from these progeroid animals.
Likewise, we found that miR-29 upregula-
tion was also a characteristic feature of
different tissue samples obtained from
old mice. Interestingly, miR-29 levels also
correlate with age in human and macaque
brain cortex28 and its expression is down-
regulated in Ames dwarf mice, that dis-
play a delay in the onset of aging.29
Collectively, these findings suggest a more
general role for miR-29 family members
in the regulation of processes associated
with normal and pathological aging.
Taking into account that Zmpste24-null
mice present nuclear abnormalities linked
Figure 2. miRNA contribution to accelerate aging. The chronic DNA damage caused by the nuclear
envelope abnormalities present in Zmpste24-deficient mice activates miR-29 transcription, which in
turn represses several key regulators of cell proliferation and senescence. miR-29 targeting of
Ppm1d, p85-a and Cdc42 converge in p53 signaling activation, which enhances the DNA damage
response, reducing cell proliferation and triggering cellular senescence. In addition, B-Myb
repression by this family of miRNAs could also be contributing to the senescence phenotype
present in Zmpste24-deficient mice by controlling important cell cycle regulators. On the other
hand, miR-1 upregulation in liver and other tissues participates in the somatotroph axis
deregulation present in the mutant mice by repressing Igf-1 expression. This phenomenon is part
of an adaptive response aimed to preserve somatic maintenance by re-allocating energy resources.
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to altered chromatin architecture and p53
pathway activation,31,35 we also evaluated
whether miR-29 upregulation was asso-
ciated with a chronic response to genomic
damage. In agreement with this hypo-
thesis, we observed that miR-29 progres-
sively accumulated during in vitro culture
of both wild-type and Zmpste24-null adult
fibroblasts, reaching the maximum expres-
sion at replicative senescence. Likewise,
we confirmed that miR-29 is transcrip-
tionally activated upon genotoxic treat-
ment with doxorubicin and that this
phenomenon is associated with the DNA
damage response, since p53-deficient,
ATM-deficient or ATR-Seckel fibroblasts
fail to induce miR-29 expression upon
this treatment.30 Consistent with a role
for miR-29 in the modulation of DNA
damage response, functional studies
demonstrated that transfection of miR-29
precursor molecules reduces cell prolifera-
tion and viability and induces senescence
in wild-type primary fibroblasts.30 Further-
more, miR-29 inhibition displayed the
opposite effect and rescued the proliferat-
ive defects and the senescence phenotype
of Zmpste24-null fibroblasts. Finally, we
identified the Ppm1d/Wip1 phosphatase
as a candidate target to mediate the
effects of miR-29. Ppm1d is a key
regulator of the DNA damage response
that dephosphorylates a wide variety of
proteins such as p53, Chk1, Chk2, p38,
c-H2AX and ATM.36,37 By using lucifer-
ase-based assays involving the 3' UTR of
Ppm1d, we demonstrated that this phos-
phatase is a bona fide target of miR-29.
Moreover, functional in vitro studies
showed that these miRNAs are able to
modulate p53 phosphorylation at Ser15,
which is the residue targeted by Ppm1d.30
According to these results, we propose that
aging or chronic DNA damage activates
a regulatory circuit involving Ppm1d and
p53 which, in turn, enhances the DNA
damage response and modulates cell proli-
feration, viability and senescence (Fig. 2).
Interestingly, it has also been reported
that miR-29 and miR-30 are upregulated
upon induced and replicative senescence
in an Rb-dependent manner and that
both miRNAs regulate this process by
direct repression of B-Myb expression.38 In
addition, Park et al.39 have demonstrated
that miR-29 targeting of p85a and
CDC42 activates p53 and regulates cell
viability in human cells. Taken together,
these data suggest that the miR-29 family
plays an essential role in the regulation of
cell proliferation, viability and senescence
by controlling multiple overlapping path-
ways. In agreement with these observa-
tions, numerous works have attributed a
tumor suppressor function for miR-29 in
a variety of human malignancies, including
hepatocellular carcinoma,40 cholangiocar-
cinoma,41 different types of leukemias,42-45
lung carcinoma,46 rhabdomyosarcoma47
and pleural mesothelioma.48 These studies
have also identified multiple miR-29
targets whose downregulation could con-
tribute to explain the tumor-suppressive
activity of this miRNA. These targets
include DNMT3A, DNMT3B, MCL1,
BCL2, SKI, CDK6, TET1, YY1 and
TCL1. Based on this information, it is
tempting to speculate that the miR-29
family of miRNAs represents a novel
example of molecules that support the
antagonistic pleiotropy concept,1 due to
their ability to play a beneficial anti-tumor
role in the reproductive age that turns into
a detrimental prosenescent function later
in life.
GeromiRs, a New and Expanding
Group of miRNAs
In addition to the regulation of senescence
by miR-29 and miR-30, a growing
number of miRNAs are arising as import-
ant modulators of conserved pathways
or processes that have been extensively
linked to aging (Table 1). Although it will
be necessary to generate animal models
with loss- or gain-of-function in specific
miRNA activities to uncover their real
contribution to aging, these miRNAs—
that we propose to call geromiRs—
represent a new group of molecules which
may be involved in the regulation of both
normal and pathological aging processes.
Thus, several works have revealed a
functional role for miRNAs in senescence
modulation through different mechanisms.
For example, miR-20a repression of LRF
(leukemia/lymphoma related factor) in
Table 1. miRNAs associated with aging in different organisms
miRNA Targets Species Pathway Ref.
lin-4 lin-14 C. elegans Insulin/Igf-1 19
miR-71, miR-238, miR-239, miR-246 Not validated C. elegans Insulin/Igf-1, DDR 20
miR-29 Ppm1d Mouse DDR-p53 30
p85a, CDC42 Human DDR-p53 39
miR-29, miR-30 B-MYB Human E2F/Rb-B-Myb 38
miR-1 Igf-1 Mouse Insulin/Igf-1 33
miR-20a Lrf Mouse p19-p53 49
miR-24 p16INK4a Human p16-pRb 50
miR-106a p21CDKN1a Human p53-p21 51
miR-146a/b IRAK1 Human IL-1-IRAK-NFkB 52
NOX4 Human NOX4-ROS-senescence 53
miR-200c ZEB1 Human ZEB1-p21 54
BMI Human BMI-1-p16/p21 68
miR-217 SIRT1 Human SIRT1-p53 55
miR-34 SIRT1 Human SIRT1-p53 57
miR-519 HuR Human HuR-SIRT1-p53 56
miR-22 SIRT1, CDK6,SP1 Human p53/pRb 59
let-7b HMGA2 Human HMGA2-p16/p19 66
miR-23a, miR-26a, miR-30 HMGA22 Human HDAC-HMGA2-p16/p21 67
miR-214 EZH2 Human EZH2-p16/p21 68
miR-33 TP53 Human p53-DDR 70
DDR, DNA damage response; ROS, reactive oxygen species
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murine fibroblasts activates p19ARF and
p16INKa and triggers cellular senescence,49
whereas miR-24 decrease in senescent
human fibroblasts is in part responsible
for p16INKa up-modulation.50 Similarly,
the five members of the miR-106b
family, including the aforementioned
miR-20a, are downregulated in stress-
induced senescence.51 miR-106a also con-
tributes to this process by facilitating p21
upregulation.51 Moreover, miR-146a/b
controls the senescence-associated secret-
ory phenotype of human fibroblasts by
a negative feedback loop that involves
IRAK1 (IL-1 receptor-associated kinase 1)
repression, thereby limiting IL-6 and IL-8
expression.52 Interestingly, miR-146a is
downregulated in aging human endothe-
lial cells and causes NOX4 upregulation,
which in turn increases ROS production
and induces senescence.53 Similarly, ROS-
induced senescence in human endothelial
cells activates miR-200c expression, which
further contributes to this process by
targeting ZEB1 expression, a key regu-
lator of epithelial-mesenchymal transition
that promotes p21 upregulation.54
The sirtuin pathway, which extends
longevity in yeast, worms and flies,3 is
also influenced by miRNAs. Thus, miR-
217 upregulation in human endothelial
cells during aging reduces Sirt1 activity
and promotes senescence,55 whereas miR-
519 targeting of the RNA binding protein
HuR decreases Sirt1 protein levels and
contributes to human fibroblast senes-
cence.56 Likewise, members of the miR-
34 family are transcriptionally activated
by p53 and facilitate a positive feedback
loop by targeting Sirt1 expression and
influencing cell cycle progression, sen-
escence and apoptosis.57,58 Additionally,
miR-22 also targets Sirt1 as well as CDK6
and SP1, and promotes senescence in both
normal and tumor cells.59 Similarly to the
sirtuin pathway, the IGF-1/insulin signal-
ing is also regulated by miRNAs. As
discussed above, several miRNAs have
been shown to modulate longevity in C.
elegans through this pathway,19,20 whereas
we have recently described the anomal-
ous upregulation of miR-1, which targets
Igf-1, in premature aging mice.33 In addi-
tion, miR-206 and miR-320 also target
this somatotroph axis protein in rats,60,61
and human miR-145 represses the expres-
sion of IGF-1 receptor and its substrate,
IRS-1.62
Finally, the decay of adult stem cells
self-renewal and pluripotency abilities is
considered a key determinant in the age-
associated decline of tissue homeostasis
and maintenance and there are evidences
that miRNAs could regulate some aspects
of these processes.63 Thus, recent reports
have described senescence or age-related
changes in miRNAs of human or rhesus
macaque mesenchymal stem cells.64,65
Furthermore, the loss of self-renewal
potential in old neural stem cells has been
linked to age-dependent upregulation of
let-7b, which in turn inhibits HMGA2
expression, a repressor of the INK4a/ARF
locus.66 In relation to this work, Lee
et al.67 have identified miR-23a, miR-
26a and miR-30 as HMGA2-targeting
miRNAs that accelerate senescence in
human umbilical cord blood-derived
multipotent stem cells (hUCB-MSCs).67
Likewise, miR-200c and miR-214
upregulation in hUCB-MSCs senescence
contributes to this process by targeting
BMI1 and EZH2, respectively,68 and the
miR-106b-25 cluster regulates adult neural
stem cell proliferation and neuronal differ-
entiation in mice.69 In this regard, it is
also remarkable that miR-33 repression of
TP53 expression has been shown to regu-
late hematopoietic stem cell self-renewal.70
In conclusion, the discovery of miRNAs
has opened a new chapter in aging
research that could help to achieve a
deeper knowledge of the molecular net-
work underlying this complex process.
Although we are far from understanding
the precise involvement of these mole-
cules in the multiple age-related cell and
tissue changes, solid evidences from the
literature support an important role for
the growing group of geromiRs in aging
modulation. Moreover, the recent adv-
ances in strategies to effectively block
specific miRNA activities in vivo may also
facilitate new therapeutic opportunities to
delay or ameliorate age-related alterations
as well as premature aging syndromes
including those caused by alterations in
the nuclear envelope.
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